Skip to content
DataLookout
Menu

NCT07900516

A Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Cancer.

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

ORR
Timeframe: up to 18 weeks

Secondary (6)

Change in Ki67 from Baseline to Surgery
Change in Ki67 from Week 2 to Surgery
CCCA
pCR
RCB 0-1
Show 1 moreShow less
Incidence and Severity of AEs/SAEs

Arms and interventions

Adaptive Culmerciclib Neoadjuvant Therapy for HR+/HER2- Breast CancerExperimental

Drugs: Kumoxili, Docetaxel, Epirubicin, Cyclophosphamide, Letrozole, Everolimus (Afinitor®)

Sites

1 site in 1 country

  • The First Affiliated Hospital of Nanjing Medical UniversityNanjing, Jiangsu, China